How can psychedelic substances facilitate research into and treatment of psychiatric disorders?

How can psychedelic substances facilitate research into and treatment of psychiatric disorders?

Essay by Josephine Marschall. Edited by Marco Aqil. 

 

Researchers in biological psychiatry are currently progressing within a ‘third wave’ of discussions, as described by Henrik Walter [1], to develop new approaches for investigating and classifying psychiatric disorders. According to Walter, the first wave of biological psychiatry was characterized by the linking of  mental disorders to physiological processes, while the second wave was driven by the discoveries that genetics and medication could influence mental disorders. Now, in the face of under-powered research and overestimation of neurobiological explanations, third wave discussions highlight the importance of big data-driven multilevel approaches using predictive modelling and allocate emphasis on the ‘mental’ of mental disorders in the search for aetiology and treatment. Yarkoni and Westfall [2] suggest taking into account a range of epistemological levels, including environmental and behavioral, while modeling psychiatric disorders; and subsequently evaluating the capacity of these models to predict disorder-specific symptoms. Walter suggests that psychiatric disorders may be described as disorders of consciousness and/or intentionality, and that a philosophy of mind perspective can help to better understand these psychological constructs and how they might relate to neurological mechanisms. In this essay, I suggest that research with psychedelic substances can, to a certain extent, facilitate these goals.

 

Early impact of psychedelic substances

In 1956, Humphry Osmond [3] first classified serotonergic hallucinogens as ‘psychedelic’, meaning ‘mind-manifesting’. He chose this name to highlight their capacity to reveal latent or unconscious aspects of the mind.

Researchers had already begun to investigate psychedelic substances in the late 1930s [4]. This was at the beginning of the ‘second wave’ of biological psychiatry, when the potential neurochemical underpinnings of psychiatric disorders were first hypothesized. Psychedelic research of the time sparked models and theories still acknowledged in biological psychiatry today.  Researchers investigating the psychoactive properties of mescaline, a serotonergic hallucinogen, were among the first to develop a neurochemical model of a psychosis [5,6]. Instead of taking the usual backward-engineering approach to investigating a disorder, they were the first to attempt manipulating neurobiology to induce symptoms which together satisfied the criteria of a classified mental disorder. This later led to the still prominent NMDA model of schizophrenia [7-9]. Insights regarding the neurochemical mechanisms of serotonin were largely influenced by the discovery and research on a chemical with a structure very similar to serotonin: lysergic acid diethylamide, much better known today as LSD. The effects of both of these chemicals in the brain were studied during the same period of time and it was quickly recognized that LSD interacts with the processes of serotonin [10]. Since LSD and other serotonergic hallucinogens had already been used to model psychosis, LSD became a tool to study the role of serotonin on behavior. This research launched great academic interest in brain chemistry and catalyzed the idea that neurochemical events could influence behavior and thereby play a role in psychopathology [11,12]. At the same time, psychiatrists were realizing that psychedelic substances also showed potential for treating various mental disorders [4]. Unfortunately, the inferences we can make using these early studies are limited because they employed outdated methodologies and often did not implement placebo-control groups.

 

How can psychedelics facilitate goals of biological psychiatry today?

Much in the same way as early psychedelic research helped illuminate the relations between certain mental phenomena and the underlying neurochemical processes, so can future psychedelic research help elucidate the links between cognition and biology. A major focus of current biological psychiatry is to view psychiatric disorders as interacting and dynamic processes which are not just of various neuro-biological levels, but also mental and environmental [1]. Psychedelics may help develop this perspective since their effects can be studied from a very broad range of epistemological levels, including pharmacological, psychological, clinical, philosophical, anthropological, and societal levels. Through stimulating serotonin receptors, psychedelics initiate  deep alterations in common mental functions including basic cognitive processes and mental constructs (e.g. working memory and the sense of self) [13].  Thus, research using psychedelic substances is intrinsically multi-level and can help elucidate the biological mechanisms underlying various properties of the mind. Moreover, clinical treatments with these substances prescribe a multi-level approach, combining the manipulation of neurobiology with psychotherapeutic strategies and specific treatment settings. Furthermore, the study of psychedelics may help bridge western biological psychiatry with indigenous healing traditions, as well as shedding light on the role of spirituality and the sense of “awe” in well-being and treatment.

 

Investigating the ‘mental’ in mental disorders: The sense of self

Discussions in philosophy of mind have strong implications for our concept of ‘self’: what the function of ‘me’ is and how this experience comes about. The concept of self is also relevant in discussions regarding mechanisms and symptoms of various psychiatric disorders [14]. The sense of self in depressive [15] and anxiety [16] disorders is subject to evaluations of inadequacy, in narcissistic personality disorder [17] the self is grandiositized, in dissociative identity disorder [18] it is fragmented, in schizophrenia [19] some aspects of self-concept are disrupted.

For decades, researchers and psychedelic-drug users have reported that psychedelics can strongly disrupt the sense of self, and that this “disintegration” of the self is part of the core of the psychedelic experience.  These reports initiated the development of questionnaires to assess self-disintegration [20,21], studies on the neural correlates of self [22], and facilitated the development of philosophical theories of the self (ie. narrative and embodied self [23], self as an emergent property of binding processes [24]). Researchers have further hypothesized that this self-disintegration, also called drug-induced ego-dissolution can lower psychological defenses and that in therapy this disintegration can provide the patient with sufficient space to reconstruct a more adaptive self-concept [25]. Indeed findings thus far reveal that the drug-induced ego-dissolution, when experienced with positive emotions (labelled ‘oceanic boundless’), was associated with improved clinical outcomes in patients with depression [26] and well-being in patients with life-threatening cancer [27]. Thus, by providing a biochemical model of self-disintegration, psychedelics can aid further investigations of the construction and mechanisms of the self-concept. These investigations could contribute to biological psychiatry by elucidating a mental property that is often disturbed in psychiatric patients and by prompting theories on treating such disturbances [28]. Of course it is important to recognize that the self-disintegration as modeled by psychedelics may not generalize to self-disintegration through other means. Nonetheless, we can consider psychedelics as tools to biochemically manipulate certain mental functions. Moreover, we can allow research with psychedelics to inspire us in the direction of modelling mental functions and behaviors through new means, such as novel substances, or less invasive techniques.

 

From multilevel models to multilevel treatment: Psychedelic-assisted therapy

Currently, the most common approach to multilevel treatment entails considering several techniques that have independently shown promising effects and attempting to combine them in order to maximize treatment outcomes [29].  For example, medications might be prescribed in order to sufficiently stabilize a patient to engage in psychotherapy. The administration of psychedelics in therapy is often termed ‘psychedelic-assisted therapy’ or ‘psychedelic psychotherapy’ and inherently develops this multilevel approach further by investigating the synergistic effects of biochemical alterations with psycho-therapeutic strategies [30]. This synergistic effect is hypothesized to lower psychological  defenses, facilitate adaptive emotional insights, increase the malleability of the patient’s belief system, and allow stronger access to autobiographical memories [31,32]. The clinical trials thus far suggest that only a few sessions are needed to obtain clinically significant positive outcomes, and that these improvements can remain significant after 6 months [33-36] and up to 4.5 years [27]. This also indicates that psychedelic-assisted therapy could be more cost- and time-efficient than most current treatments [37,38]. Researchers are now attempting to clarify the specific biochemical process by which psychedelics aid therapy and which psycho-therapeutic strategies provide the most synergistic effects.

Discussions regarding the role of environmental factors in psychiatric treatment are currently limited to whether a patient requires inpatient care or can be treated at home.  Thus, environmental factors contributing to treatment are largely under-studied and likely underestimated. Research on the placebo effect [39] provides a first glimpse that the visual characteristics and rituals of psychiatric medications and procedures can have significant effects on clinical outcomes. The psychedelic experience is greatly influenced by environmental factors,  and thus psychedelic-assisted treatment requires optimizing the treatment setting[40]. Environmental factors that can influence the treatment include music [41], nature, and familial items [33,43]. Researchers uncovering which variables to consider in psychedelic-assisted therapy are also studying indigenous contexts where these substances are combined with specific rituals for healing in the safety of nature and a supportive community [44-45].  Such an approach could inspire us to reconsider environmental influences during treatment and reminds us that we might gain important insights from studying healing rituals of non-Western cultures. In this way, psychedelics present an opportunity to investigate the interaction between biological, psychological and environmental mechanisms in psychiatric treatment, and psychedelic-assisted therapy can be viewed as one of the first initiatives towards developing multi-level treatments.

 

Spiritual well-being as a new level to the multilevel approach of third wave psychiatry?

Health as defined by the World Health Organization in their constitution [46] concerns three dimensions: physical, mental, and social.  Already in 2003, researchers from Thailand [47] suggested expanding this biomedical model to include a 4th dimension: spiritual well-being. Since then, the World Health Organization has taken steps to  assess and incorporate spiritual well-being by developing a quality of life scale [48] that assesses spirituality, religiousness, and personal beliefs. Researchers in biological psychiatry have also investigated the effects of spiritual or religious attitudes on  well-being, proposing that clinicians should assess and cater to the spiritual needs of their patients [49-52]. The findings thus far reveal that religious or spiritual attitudes may serve as a coping or protective mechanism for mental health and may facilitate remission from psychiatric disorders [53,54].

Although a dimension of spirituality may be a beneficial addition to multilevel approaches in biological psychiatry, researchers have struggled both to define the concept and to investigate its underlying mechanisms. In contemporary psychedelic research, the term ‘mystical experience’ is often used to describe the spiritual or religious dimension of an intense psychedelic experience [55-57]; notably, the extent of reported psychedelic-induced mystical experience significantly correlates with positive clinical outcomes in patients with nicotine addiction [58], anxiety and depression [34,36]. Some researchers have suggested that the sense of awe intrinsic in such experience might underlie the beneficial effects of psychedelics [59]. These findings suggest that spiritual experiences, in relation to mental health, deserve closer scrutiny; and that psychedelics could serve as a potent tool to help us define and study spirituality and its effects.

 

Limitations of current psychedelic research

The findings reported above suggest that biological psychiatry can benefit from implementing psychedelic research programs; but it is also important to note that the biological mechanisms by which psychedelics initiate these benefits are currently not fully clear. Modern psychedelic neuroscience is still in its infancy, and because of the difficulties intrinsic in administering powerful psychoactive substances while performing neuroimaging, the few published studies lack sufficient power to draw strong conclusions. All 13 neuroimaging studies were conducted on only 9-15  subjects, of which 0-5 subjects were female [60-70]. Moreover, these studies either investigated the effects over the full brain or on a large number of regions of interests (ROIs; e.g. 401 ROIs [67]). Although the effect sizes appear quite large, neuroimaging studies with a broad focus and small sample sizes are susceptible to false positives with large effects [71]. Moreover, most of the above cited fMRI studies collected scans for only 6-7 minutes, which may not be sufficient to capture a potentially dynamic psychedelic effect and could explain some of the variability between studies. Lastly, although several studies used placebo-control groups, experimental blinding in psychedelic research is difficult to achieve since psychedelics have very strong and specific effects. Participants can thus often tell what condition they are in, meaning that condition-related expectations may have influenced the results.

Due to these limitations, it is hard to draw strong and specific conclusions from the neuroimaging studies published thus far. The current consensus regarding the general biological mechanism is that the psychedelic effects are driven by their stimulation of the serotonin 2a receptors [60], which leads to disintegration of functionally connected regions (the default mode network, in particular), reduced activation in connector hubs, and increased functional connectivity between regions that are normally not connected. In this way, psychedelics are thought to increase the entropy of brain activity, enabling a general state of unconstrained cognition [63,72]. How this increased entropy exactly relates to the self, to spirituality, and to therapeutic outcomes remains to be investigated with adequately powered designs.

 

Conclusion

Research with psychedelics could facilitate the field of biological psychiatry in three ways: by providing an opportunity to neurochemically investigate certain mental phenomena such as the self, by using a multilevel approach in both research and treatment with important emphasis on environmental factors, and by inspiring us to learn from non-Western cultures and ‘non-scientific’ concepts such as spirituality. It is important to note that research with psychedelics is still in the beginning stages and the quality of, especially neuroimaging, research must be improved. Fortunately, these  issues can be tackled by motivating researchers in biological psychiatry to contribute to the study of these substances.

 

References

  1. Walter, H. (2013). The third wave of biological psychiatry. Frontiers in Psychology, 4. doi: 10.3389/fpsyg.2013.00582
  2. Yarkoni, T., & Westfall, J. (2017). Choosing Prediction Over Explanation in Psychology: Lessons From Machine Learning. Perspectives on Psychological Science, 12(6), 1100–1122. doi: 10.1177/1745691617693393
  3. Osmond, H. (1957). A Review Of The Clinical Effects Of Psychotomimetic Agents. Annals of the New York Academy of Sciences, 66(3), 418–434. doi: 10.1111/j.1749-6632.1957.tb40738.x
  4. Sessa, B. (2016). The History of Psychedelics in Medicine. Handbuch Psychoaktive Substanzen, 1–26. doi: 10.1007/978-3-642-55214-4_96-1
  5. Guttmann, E. (1936). Artificial Psychoses Produced by Mescaline. Journal of Mental Science, 82(338), 203–221. doi: 10.1192/bjp.82.338.203
  6. Stockings, G. T. (1940). A Clinical Study of the Mescaline Psychosis, with Special Reference to the Mechanism of the Genesis of Schizophrenic and Other Psychotic States. Journal of Mental Science, 86(360), 29–47. doi: 10.1192/bjp.86.360.29
  7. Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999). NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research, 33(6), 523–533. doi: 10.1016/s0022-3956(99)00029-1
  8. Moghaddam, B., & Krystal, J. H. (2012). Capturing the Angel in “Angel Dust”: Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans. Schizophrenia Bulletin, 38(5), 942–949. doi: 10.1093/schbul/sbs075
  9. González-Maeso, J., & Sealfon, S. C. (2009). Psychedelics and schizophrenia. Trends in Neurosciences, 32(4), 225–232. doi: 10.1016/j.tins.2008.12.005
  10. Shore, P. A., Silver, S. L., & Brodie, B. B. (1955). Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia, 11(7), 272–273. doi: 10.1007/bf02161252
  11. Whitaker-Azmitia, P. M. (1999). The Discovery of Serotonin and its Role in Neuroscience. Neuropsychopharmacology, 21. doi: 10.1038/sj.npp.1395355
  12. Woolley, D. W., & Shaw, E. (1954). A Biochemical And Pharmacological Suggestion About Certain Mental Disorders. Proceedings of the National Academy of Sciences, 40(4), 228–231. doi: 10.1073/pnas.40.4.228
  13. Vollenweider F. X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues in clinical neuroscience, 3(4), 265–279.
  14. Davidson, L., & Strauss, J. S. (1992). Sense of self in recovery from severe mental illness. British Journal of Medical Psychology, 65(2), 131–145. doi: 10.1111/j.2044-8341.1992.tb01693.x
  15. Kopala‐Sibley, D. C., & Zuroff, D. C. (2019). The self and depression: Four psychological theories and their potential neural correlates. Journal of Personality, 88(1), 14–30. doi: 10.1111/jopy.12456
  16. Muris, P. (2002). Relationships between self-efficacy and symptoms of anxiety disorders and depression in a normal adolescent sample. Personality and Individual Differences, 32(2), 337–348. doi: 10.1016/s0191-8869(01)00027-7
  17. Sedikides, C., Ntoumanis, N., & Sheldon, K. M. (2018). I am the chosen one: Narcissism in the backdrop of self-determination theory. Journal of Personality, 87(1), 70–81. doi: 10.1111/jopy.12402
  18. Sar, V., Dorahy, M., & Krüger, C. (2017). Revisiting the etiological aspects of dissociative identity disorder: a biopsychosocial perspective. Psychology Research and Behavior Management, Volume 10, 137–146. doi: 10.2147/prbm.s113743
  19. Moe, A. M., & Docherty, N. M. (2014). Schizophrenia and the sense of self. Schizophrenia bulletin, 40(1), 161–168. doi:10.1093/schbul/sbt121
  20. Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in human neuroscience, 10, 269. doi:10.3389/fnhum.2016.00269
  21. Dittrich, A. (1998). The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans. Pharmacopsychiatry, 31(S 2), 80–84. doi: 10.1055/s-2007-979351
  22. Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015). Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Human Brain Mapping, 36(8), 3137–3153. doi: 10.1002/hbm.22833
  23. Millière, R. (2017). Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution. Frontiers in Human Neuroscience, 11. doi: 10.3389/fnhum.2017.00245
  24. Letheby, C., & Gerrans, P. (2017). Self unbound: ego dissolution in psychedelic experience. Neuroscience of Consciousness, 2017(1). doi: 10.1093/nc/nix016
  25. Fischman, L. G. (2019). Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy. Neuropsychoanalysis, 21(2), 53–78. doi: 10.1080/15294145.2019.1689528
  26. Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Frontiers in Pharmacology, 8. doi: 10.3389/fphar.2017.00974
  27. Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155–166. doi: 10.1177/0269881119897615
  28. Nour, M. M., & Carhart-Harris, R. L. (2017). Psychedelics and the science of self-experience. British Journal of Psychiatry, 210(3), 177–179. doi: 10.1192/bjp.bp.116.194738
  29. Craighead, W. E., & Dunlop, B. W. (2014). Combination Psychotherapy and Antidepressant Medication Treatment for Depression: For Whom, When, and How. Annual Review of Psychology, 65(1), 267–300. doi: 10.1146/annurev.psych.121208.131653
  30. Watts, R., & Luoma, J. (2019). The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science. doi: 10.1016/j.jcbs.2019.12.004
  31. Richards, W. A. (2016). Psychedelic Psychotherapy: Insights From 25 Years of Research. Journal of Humanistic Psychology, 57(4), 323–337. doi: 10.1177/0022167816670996
  32. Carhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., … Nutt, D. J. (2012). Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 200(3), 238–244. doi: 10.1192/bjp.bp.111.103309
  33. Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall,  Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Scientific Reports,7(1). doi:10.1038/s41598-017-13282-7
  34. Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., … Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. doi: 10.1177/0269881116675513
  35. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., Mckay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry,68(1), 71. doi:10.1001/archgenpsychiatry.2010.116
  36. Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. doi: 10.1177/0269881116675512
  37. Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm. Canadian Medical Association Journal, 187(14), 1054–1059. doi: 10.1503/cmaj.141124
  38. Schenberg, E. E. (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology, 9. doi: 10.3389/fphar.2018.00733
  39. Jonas, W. B. (2011). Reframing placebo in research and practice. Philosophical Transactions of the Royal Society B: Biological Sciences, 366(1572), 1896–1904. doi: 10.1098/rstb.2010.0405
  40. Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267. doi: 10.1177/0269881116677852
  41. Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., … Carhart-Harris, R. (2018). The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology, 235(2), 505–519. doi: 10.1007/s00213-017-4820-5
  42. Metzner, R. (1998). Hallucinogenic Drugs and Plants in Psychotherapy and Shamanism. Journal of Psychoactive Drugs, 30(4), 333–341. doi: 10.1080/02791072.1998.10399709
  43. Winkelman, M. J. (2017). The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology. Frontiers in Neuroscience, 11. doi: 10.3389/fnins.2017.00539
  44. Goldsmith, N. M. (2011). Psychedelic healing: the promise of entheogens for psychotherapy and spiritual development. Rochester, VT: Healing Arts Press.
  45. Trichter, S., Klimo, J., & Krippner, S. (2009). Changes in Spirituality Among Ayahuasca Ceremony Novice Participants. Journal of Psychoactive Drugs, 41(2), 121–134. doi: 10.1080/02791072.2009.10399905
  46. World Health Organization. (n.d.). Constitution. Retrieved from https://www.who.int/about/who-we-are/constitution.
  47. Chuengsatiansup, K. (2003). Spirituality and health: an initial proposal to incorporate spiritual health in health impact assessment. Environmental Impact Assessment Review, 23(1), 3–15. doi: 10.1016/s0195-9255(02)00037-9
  48. World Health Organization. (2002). WHOQOL-SRPB field-test instrument : WHOQOL spirituality, religiousness and personal beliefs (‎SRPB)‎ field-test instrument : the WHOQOL-100 questions plus 32 SRPB questions. Retrieved from https://apps.who.int/iris/handle/10665/77777.
  49. Dsouza, R. (2003). Incorporating a Spiritual History into a Psychiatric Assessment. Australasian Psychiatry, 11(1), 12–15. doi: 10.1046/j.1440-1665.2003.00509.x
  50. Verghese A. (2008). Spirituality and mental health. Indian journal of psychiatry, 50(4), 233–237. doi:10.4103/0019-5545.44742
  51. Rao M. S. (2005). Spirituality in psychiatry?. Psychiatry (Edgmont (Pa. : Township)), 2(9), 20–22.
  52. Zahn, A., Reiser, F., Baumann, K., & Riemann, D. (2015). Spiritual Needs of Patients in Psychiatry and Psychotherapy and Their Utilization of Spirituality as Part of a Coping Strategy. European Psychiatry, 30, 664. doi: 10.1016/s0924-9338(15)30525-3
  53. Koenig, H. G. (2012). Religion, Spirituality, and Health: The Research and Clinical Implications. ISRN Psychiatry, 2012, 1–33. doi: 10.5402/2012/278730
  54. Lin, H.-R., & Bauer-Wu, S. M. (2003). Psycho-spiritual well-being in patients with advanced cancer: an integrative review of the literature. Journal of Advanced Nursing, 44(1), 69–80. doi: 10.1046/j.1365-2648.2003.02768.x
  55. Griffiths, R., Richards, W., Johnson, M., Mccann, U., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. doi: 10.1177/0269881108094300
  56. Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. doi: 10.1016/j.pharmthera.2018.11.010
  57. Barrett, F. S., & Griffiths, R. R. (2017). Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Behavioral Neurobiology of Psychedelic Drugs Current Topics in Behavioral Neurosciences, 393–430. doi: 10.1007/7854_2017_474
  58. Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015). Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Current Drug Abuse Reviews, 7(3), 157–164. doi: 10.2174/1874473708666150107121331
  59. Hendricks, P. S. (2018). Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry, 30(4), 331–342. doi: 10.1080/09540261.2018.1474185
  60. Vollenweider, F. (1997). Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis. Neuropsychopharmacology, 16(5), 357–372. doi: 10.1016/s0893-133x(96)00246-1
  61. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., … Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143. doi: 10.1073/pnas.1119598109
  62. Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., … Nutt, D. J. (2013). Broadband Cortical Desynchronization Underlies the Human Psychedelic State. Journal of Neuroscience, 33(38), 15171–15183. doi: 10.1523/jneurosci.2063-13.2013
  63. Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 35(11), 5442–5456. doi: 10.1002/hbm.22562
  64. Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. Journal of The Royal Society Interface, 11(101), 20140873. doi: 10.1098/rsif.2014.0873
  65. Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., … Araujo, D. B. D. (2015). The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network. Plos One, 10(2). doi: 10.1371/journal.pone.0118143
  66. Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., …Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853–4858. Doi: 10.1073/pnas.1518377113
  67. Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., … Carhart-Harris, R. (2016). Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Current Biology, 26(8), 1043–1050. doi: 10.1016/j.cub.2016.02.010
  68. Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G., & Carhart-Harris, R. L. (2017). Connectome-harmonic decomposition of human brain activity reveals dynamical repertoire re-organization under LSD. Scientific Reports, 7(1). doi: 10.1038/s41598-017-17546-0
  69. Viol, A., Palhano-Fontes, F., Onias, H., Araujo, D. B. D., & Viswanathan, G. M. (2017). Shannon entropy of brain functional complex networks under the influence of the psychedelic Ayahuasca. Scientific Reports, 7(1). doi: 10.1038/s41598-017-06854-0
  70. Deco, G., Cruzat, J., Cabral, J., Knudsen, G. M., Carhart-Harris, R. L., Whybrow, P. C., … Kringelbach, M. L. (2018). Whole-Brain Multimodal Neuroimaging Model Using Serotonin Receptor Maps Explains Non-linear Functional Effects of LSD. Current Biology, 28(19). doi: 10.1016/j.cub.2018.07.083
  71. Cremers, H. R., Wager, T. D., & Yarkoni, T. (2017). The relation between statistical power and inference in fMRI. Plos One, 12(11). doi: 10.1371/journal.pone.0184923
  72. Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., … Nutt, D. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8. doi: 10.3389/fnhum.2014.00020

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s